The concept of the heart as an endocrine organ has been attractive since the discovery of atrial natriuretic peptide. This review focuses on the second discovered natriuretic peptide from the heart-B-type natriuretic peptide (BNP), widely used as a tool in the diagnosis of heart failure (HF). Controversy remains regarding its use as a therapeutic agent in HF. This article places into perspective some of the debate and provides insights into the therapeutics of BNP and the importance of its second messenger 3′5′ cyclic guanosine monophosphate, which also is the second messenger for nitric oxide and is modulated by renal phosphodiesterases.
|Original language||English (US)|
|Number of pages||6|
|Journal||Heart Failure Clinics|
|State||Published - Oct 2008|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine